“RESPECT-ESUS”

Date: September 12, 2014|Source: Boehringer Ingelheim

“RESPECT-ESUS” – Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of Undetermined Source – Boehringer Ingelheim – Principle Investigator